Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C. Smith, Neil P. Shah, Qi Wang et al.|Nature|2012Cited by 745
Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultationPatricia Schlagenhauf, Martin P. Grobusch, François Chappuis et al.|The Lancet Infectious Diseases|2014Cited by 248
Crenolanib is a selective type I pan-FLT3 inhibitorCatherine C. Smith, Neil P. Shah, Elisabeth A. Lasater et al.|Proceedings of the National Academy of Sciences|2014Cited by 211
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutationsTheodore C. Tarver, Catherine C. Smith|Blood Advances|2020Cited by 76
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AMLBogdan Popescu, Catherine C. Smith|Cell Reports Medicine|2023Cited by 11